Professor Hilary Thomas, Chief Medical Advisor at KPMG in the UK, comments.
Professor Hilary Thomas, Chief Medical Advisor at KPMG in the UK, comments:
“The UK has taken a lead globally in this area for some time now. Whether you want to call it a market failure, or a broken business model, the fact is that the incentives are not aligned for the development of much needed new classes of antimicrobials.
“It’s a very exciting and much needed initiative and I only hope that when the learning is shared with other countries and healthcare systems, it will be adopted and spread to avoid the enormous financial and, more importantly, human costs that are otherwise likely.”
For media enquiries only, please contact:
Helen Jackson, KPMG Corporate Communications
M: 0118 3731 479
Follow us on twitter: @kpmguk
KPMG Press Office: +44 (0)207 694 8773
KPMG LLP, a UK limited liability partnership, operates from 22 offices across the UK with approximately 16,300 partners and staff. The UK firm recorded a revenue of £2.338 billion in the year ended 30 September 2018. KPMG is a global network of professional firms providing Audit, Tax, and Advisory services. It operates in 154 countries and has 200,000 professionals working in member firms around the world. The independent member firms of the KPMG network are affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. Each KPMG firm is a legally distinct and separate entity and describes itself as such.
© 2021 KPMG LLP a UK limited liability partnership and a member firm of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.
For more detail about the structure of the KPMG global organisation please visit https://home.kpmg/governance.